<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00679718</url>
  </required_header>
  <id_info>
    <org_study_id>03-103</org_study_id>
    <nct_id>NCT00679718</nct_id>
  </id_info>
  <brief_title>A Study of INS365 Ophthalmic Solution in Patients With Moderate to Severe Dry Eye Disease</brief_title>
  <official_title>A Multi-Center, Double-Masked, Randomized, Placebo-Controlled, Dose-Ranging Study of Multiple Ocular Instillations of INS365 Ophthalmic Solution vs. Placebo in Patients With Moderate to Severe Dry Eye Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <brief_summary>
    <textblock>
      To evaluate the efficacy and safety of INS365 Ophthalmic Solution when applied topically in
      patients with moderate to severe dry eye disease.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2000</start_date>
  <completion_date type="Actual">July 2000</completion_date>
  <primary_completion_date type="Actual">July 2000</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Schirmer scores</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Corneal staining</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Conjunctival staining</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Tear break-up time</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in artificial tear usage</measure>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient-reported improvement of foreign body sensation</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual acuity</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator global severity assessment</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient-reported dry eye symptoms other than foreign body sensation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomicroscopy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ophthalmoscopy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IOP</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Dry Eye Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>diquafosol tetrasodium (INS365) ophthalmic solution</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Best corrected visual acuity of at least +0.7 ETDRS

          -  Six month history of dry eye disease

          -  Mild severity in two out of five symptoms

          -  Unanesthetized Schirmer score of less than or equal to 7mm

          -  Corneal fluorescein staining greater than or equal to 4 out of 15 or lissamine green
             conjunctival staining of greater than or equal to 5 out of 18

        Exclusion Criteria:

          -  Nasal stimulated Schirmer score of less than 3mm

          -  Have ongoing ocular infection

          -  Have congenitally absent meibomian or lacrimal glands

          -  Have had punctal occlusion within a specified time prior to study

          -  Wear contact lens and refuse to remove them

          -  Have other excluded eye conditions.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Clinical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <verification_date>August 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 15, 2008</study_first_submitted>
  <study_first_submitted_qc>May 16, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2008</study_first_posted>
  <last_update_submitted>August 26, 2015</last_update_submitted>
  <last_update_submitted_qc>August 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

